Drug Profile
C3BS CQR 1
Alternative Names: Autologous cardiac progenitor stem cell therapy - Celyad Oncology; Bone marrow derived mesenchymal cardiopoietic cells - Celyad Oncology; C-Cure; C3BR-CQR-1; C3BS-CQR-1; Congestive heart failure cardiopoietic regenerative therapy - Celyad OncologyLatest Information Update: 15 Jun 2020
Price :
$50
*
At a glance
- Originator Cardio3 BioSciences
- Developer Celyad Oncology
- Class Heart failure therapies; Mesenchymal stem cell therapies; Stem cell therapies
- Mechanism of Action Cell replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Discontinued Chronic heart failure
Most Recent Events
- 10 Jun 2020 Celyad is now called Celyad Oncology
- 17 May 2018 Phase-III clinical trials in Chronic heart failure in USA (Intracoronary)
- 01 Sep 2017 C3BS CQR 1 is still at phase III development stage for Chronic heart failure in European Union, Switzerland, Israel and Serbia (Intracoronary)